About the Company
We do not have any company description for Lucid Diagnostics Inc. at the moment.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
4
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LUCD News
LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD ...
PAVmed Inc. (PAVM)
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq ...
Lucid Diagnostics: Strong Buy Rating with Significant Market Potential Despite Near-Term Losses
Edward Woo, an analyst from Ascendiant, maintained the Buy rating on Lucid Diagnostics (LUCD – Research Report). The associated price target is $8.00. Edward Woo has given his Buy rating due to ...
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
NEW YORK, April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned ...
Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq ...
Lucid Diagnostics holds Buy rating, and stock target on company's performance
On Monday, Lucid (NASDAQ:LCID) Diagnostics Inc (NASDAQ:LUCD) retained its Buy rating and $2.50 stock price target from an investment firm. Following the release of the company’s fourth-quarter results ...
Lucid to report Q1 earnings amid cash burn, waning EV growth
The startup produced 1,728 Air sedans in the first quarter, running behind its 2024 forecast of 9,000 vehicles. Lucid plans to launch a second model, the Gravity crossover, this year.
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
NEW YORK, April 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned ...
Lucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq ...
Lucid Diagnostics Inc LUCD
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Lucid Diagnostics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Lucid Diagnostics Inc (LUCD)
Lucid (NASDAQ:LCID) Diagnostics (ticker: LUCD) has reported a significant uptick in its revenue during the fourth quarter, with a 33% increase from the previous quarter and an 829% ...
Loading the latest forecasts...